Human parathyroid hormone for treating osteoporosis

dc.contributor.author	Lau, Henry K.	eng
dc.contributor.author	Mounsey, Anne L.	eng
dc.contributor.author	Mackler, Leslie	eng
dc.date.issued	2012	eng
dc.description.abstract	Human parathyroid hormone should be used in patients with severe osteoporosis to decrease the rate of vertebral and nonvertebral fractures. (Strength of Recommendation [SOR]: A, based on a systematic review and randomized controlled trial [RCT].) The parathyroid hormone teriparatide (Forteo) should be reserved for patients who do not respond to bisphosphonates or who have severe bone loss. (SOR: C, based on expert opinion.)	eng
dc.identifier.uri	http://hdl.handle.net/10355/12810	eng
dc.language	English	eng
dc.publisher	Family Physicians Inquiries Network	eng
dc.relation.ispartofcollection	Clinical Inquiries, 2012 (MU)	eng
dc.relation.ispartofcommunity	University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network.	eng
dc.relation.ispartofseries	American family physician, 85, no. 03 (February 1, 2012)	eng
dc.rights	OpenAccess.	eng
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.	eng
dc.subject	osteoporosis therapy	eng
dc.subject	vertebral fracture	eng
dc.subject	bone mineral density	eng
dc.subject.lcsh	Vertebrae -- Diseases	eng
dc.subject.lcsh	Bone densitometry	eng
dc.title	Human parathyroid hormone for treating osteoporosis	eng
dc.type	Article	eng

Clinical Inquiries, 2012
The items in this collection constitute volume 61 of Clinical Inquiries.